Skip to content
Checking whether you are signed in

Johnson & Johnson

JNJNew York Stock ExchangeFull coverage

Price
Loading your watchlists

Latest dossier

AI-generated

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers

How dossiers are written

Q3 of fiscal year 2026 · Published Nov 3, 2026, 5:28 PM UTC

Johnson & Johnson sells prescription drugs and medical devices, and its third quarter of fiscal 2026 showed new medicines such as TREMFYA, DARZALEX and CARVYKTI replacing the fast-shrinking STELARA: sales grew 5.9% to $25.4 billion and the company raised its full-year sales guidance again. Diluted EPS fell to $0.09 because of a $5.5 billion charge for a proposed ovarian talc settlement that still needs 95% of claimants to join, while the device business slowed for the third quarter running. The next test is 2027, when products with $4 billion to $4.5 billion of sales lose patent protection, by the CFO's count. Moatsight estimates revenue of about $105.3 billion and free cash flow of about $19.5 billion over the next four quarters.

Read the dossier

What you pay

FigureAt the close5-yr median5-yr range
P/ENo value: no close yetNo value: no price history
EV/SalesNo value: no close yetNo value: no price history
EV/EBITDANo value: no close yetNo value: no price history
Price/FCFNo value: no close yetNo value: no price history
Market capNo value: no close yet
Net debt and other claims(enterprise value minus market cap)No value: no close yet
Enterprise valueNo value: no close yet

How the business is doing

FigureLast 12 months1-year change1-yearYearly, 3 years8 quarters
Revenue$99.3B+7.8%(better for the company)+5.9%Each quarter is listed in the row's details.
Diluted EPS$6.57−36.4%(worse for the company)−21.5%Each quarter is listed in the row's details.
Free cash flow$20.6B+5.1%(better for the company)+9.4%Each quarter is listed in the row's details.
Gross margin67.6%−0.5 pp(worse for the company)−0.5 ppEach quarter is listed in the row's details.
Operating marginNo value: not in the filingsNo value: not in the filingsNo value: not in the filingsNo value: not in the filings
Net margin16.2%−11.1 pp(worse for the company)−8.4 ppEach quarter is listed in the row's details.
Share count2.449B+0.8%(worse for the company)−1.3%Each quarter is listed in the row's details.
How to read these figures
  • Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
  • 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
  • Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
  • 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
  • n/m: not meaningful, such as a rate of change from a loss.
  • Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.

Price

No closing prices are stored for this listing yet.

Facts

Exchange
New York Stock Exchange · USD
Kind
Common stock
Security
Common Stock